Skip to main content
Premium Trial:

Request an Annual Quote

Nuevolution, CRT Partner in Cancer Compound Hunt

NEW YORK (GenomeWeb News) – The Danish drug discovery firm Nuevolution said today that it will collaborate with Cancer Research Technology, the commercial branch of Cancer Research UK, to identify possible drug candidates for use in cancer treatments.

Under the collaboration, Nuevolution will use its Chemetics technology, which uses DNA labeling for small-molecule drug screening, to identify drug leads that block the activity of a number of cancer targets, the company said.

CRT will harness CRUK's cancer research network to provide biological information about the targets on which the partners plan to focus their efforts. CRT also will provide expertise in in vitro screening assays, cellular activity assays, and other drug discovery activities.

Any further pre-clinical development of promising small molecules the partners identify will be worked out under a separate agreement between Nuevolution and CRT, the company said.

Hamish Ryder, CRT's director of drug discovery for its Discovery Laboratories, said in a statement that the collaboration "will allow us to address a number of 'low-tractability' cancer targets" that have made cancer drug discovery difficult, and will enable them to assess hundreds of millions of potential compounds.

Filed under

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.